{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:45:08Z","timestamp":1773463508129,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.transproceed.2017.11.013","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T00:35:38Z","timestamp":1517618138000},"page":"142-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations"],"prefix":"10.1016","volume":"50","author":[{"given":"K.M.","family":"Baradhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.L.","family":"Aure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"El-Amm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.transproceed.2017.11.013_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.transproceed.2017.11.013_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/TP.0b013e31828555ac","article-title":"Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations","volume":"95","author":"Gracia-Ahufinger","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.11.013_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1399-3062.2007.00249.x","article-title":"Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation","volume":"10","author":"West","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2017.11.013_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","volume":"335","author":"Crumpacker","year":"1996","journal-title":"Ganciclovir. N Engl J Med"},{"key":"10.1016\/j.transproceed.2017.11.013_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1086\/514041","article-title":"High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes","volume":"176","author":"Smith","year":"1997","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.transproceed.2017.11.013_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"89","author":"Kotton","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.11.013_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31821fad25","article-title":"Incidence and outcome of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients","volume":"92","author":"Myhre","year":"2011","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:13:20Z","timestamp":1635506000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517308308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0041134517308308"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.11.013","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}